GlassScriptPhysician profile
Yvonne Haug
NPI 1366427379
$2,487.84
in general payments reported to CMS, 2019-2025
32 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $414 · 2021: $308 · 2022: $184 · 2023: $151 · 2024: $398 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $361.19 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $285.54 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $210.91 | 2019-2025 | Otezla, Repatha, Evenity |
| Allergan, INC. | $193.67 | 2019-2020 | |
| Pfizer INC. | $163.69 | 2023-2025 | |
| Abbott Laboratories | $161.67 | 2021-2025 | Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.24 | 2019-2023 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.39 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $85.54 | 2020-2024 | Airsupra |
| Sanofi-Aventis U.S. LLC | $83.33 | 2019 | |
| Abbvie INC. | $74.92 | 2021-2025 | |
| Glaxosmithkline, LLC. | $60.76 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $51.30 | 2019 | |
| Biogen, INC. | $50.36 | 2021 | |
| Si-Bone, INC. | $41.67 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $41.16 | 2022-2024 | |
| Inspire Medical Systems, INC. | $40.82 | 2024 | Inspire |
| Lundbeck LLC | $38.18 | 2024-2025 | Rexulti |
| Genentech USA, INC. | $33.19 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $31.50 | 2019 | |
| Boston Scientific Corporation | $29.20 | 2020 | |
| Radius Health, INC. | $28.92 | 2019 | |
| Redhill Biopharma INC. | $23.37 | 2020 | |
| Nevro Corp. | $21.02 | 2022 | |
| Gilead Sciences, INC. | $20.34 | 2020 | |
| Sanofi Pasteur INC. | $19.56 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $18.69 | 2025 | Rexulti |
| Shield Therapeutics INC | $17.68 | 2023 | Accrufer |
| Astellas Pharma US INC | $17.27 | 2021 | |
| Currax Pharmaceuticals LLC | $14.44 | 2024 | Contrave |
| Novartis Pharmaceuticals Corporation | $12.67 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvonne Haug listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.